Company intelligence / Profile preview

FOx Biosystems

Ownership: Private
Development stage: Commercial

Overview

FOx Biosystems has commercialized its proprietary fiber-optic SPR biosensor platform for real-time, label-free biomolecular interaction analysis. The technology enables high-quality affinity and kinetic data generation across a wide range of applications in life science research and diagnostics. The company has secured several million euros in funding and continues to expand its product offerings. No clinical results as the company does not develop therapeutics.

Therapeutic areas: Other
Modalities: Device (biosensor instruments)Diagnostic technology (label-free analysis)Platform technology (fiber-optic-based surface plasmon resonance biosensor)
Industry: Drug Discovery Services

Partnerships

KU Leuven

Beyond the preview

Go deeper on FOx Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FOx Biosystems.

Explore the full profile